Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel
Despite substantial drug development efforts, pancreatic adenocarcinoma (PDAC) remains a difficult disease to treat, and surgical resection is the only potentially curative option. Unfortunately, 80% of patients are ineligible for surgery due to the presence of invasive disease and/or distant metast...
Guardado en:
Autores principales: | Michael Pigula, Zhiming Mai, Sriram Anbil, Myung-Gyu Choi, Kenneth Wang, Edward Maytin, Brian Pogue, Tayyaba Hasan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/612ea5ff60c2440cbadd19e1c37a4e89 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021) -
Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?
por: Barbara Link, et al.
Publicado: (2021) -
Association of radiation dose intensity with overall survival in patients with distant metastases
por: Johnny Kao, et al.
Publicado: (2021) -
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas M, et al.
Publicado: (2017) -
Photodynamic therapy at the treatment of recurrent basal cell skin cancer
por: A. V. Belonogov, et al.
Publicado: (2014)